Open AccessP1428: IMPLICATIONS OF THE RUXOLITINIB (JAK1/JAK2 INHIBITOR) ON GRAFT‐VERSUS‐LEUKAEMIA EFFECT MEDIATED BY THE NK CELL.
Author(s) -
Durán C.,
Martín Cortázar C.,
Ferreras C.,
Navarro Zapata A.,
Clares Villa L.,
Alakioui K.,
Escuredo A.,
Pernas A.,
Galán V.,
Bueno D.,
Sisinni L.,
Pérez Martínez A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000848568.92492.6e
Subject(s) - ruxolitinib , degranulation , stat5 , immunology , flow cytometry , cancer research , proinflammatory cytokine , haematopoiesis , medicine , stem cell , biology , inflammation , bone marrow , myelofibrosis , microbiology and biotechnology , receptor